Y Intercept Hong Kong Ltd Takes Position in COMPASS Pathways plc (NASDAQ:CMPS)

Y Intercept Hong Kong Ltd bought a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 20,727 shares of the company’s stock, valued at approximately $131,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Blue Trust Inc. acquired a new position in COMPASS Pathways in the 2nd quarter worth $81,000. AdvisorShares Investments LLC increased its position in shares of COMPASS Pathways by 13.5% during the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock worth $362,000 after acquiring an additional 7,243 shares during the last quarter. Fore Capital LLC acquired a new position in shares of COMPASS Pathways in the second quarter worth about $181,000. Renaissance Technologies LLC boosted its holdings in COMPASS Pathways by 1,518.4% in the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after purchasing an additional 247,500 shares during the last quarter. Finally, Logos Global Management LP grew its stake in COMPASS Pathways by 349.3% during the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after purchasing an additional 901,050 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the transaction, the insider now directly owns 6,905,774 shares in the company, valued at $41,779,932.70. This represents a 27.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.25% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of recent analyst reports. HC Wainwright cut their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada cut their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th. Finally, Maxim Group dropped their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $33.60.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $3.92 on Friday. The stock has a market capitalization of $268.21 million, a PE ratio of -1.78 and a beta of 2.24. The business’s fifty day moving average price is $5.07 and its 200 day moving average price is $6.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 12-month low of $3.86 and a 12-month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter last year, the firm earned ($0.67) EPS. Equities research analysts forecast that COMPASS Pathways plc will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.